Citizens Jmp Issues Positive Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price target upped by Citizens Jmp from $85.00 to $115.00 in a research note issued to investors on Friday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the medical equipment provider’s stock.

A number of other brokerages also recently issued reports on LNTH. Jefferies Financial Group reissued a “buy” rating and set a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research report on Thursday. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, B. Riley Financial restated a “buy” rating on shares of Lantheus in a research report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.29.

Lantheus Stock Up 2.3%

Shares of NASDAQ:LNTH opened at $93.06 on Friday. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $94.86. The company has a quick ratio of 2.51, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The firm’s 50-day simple moving average is $79.69 and its 200-day simple moving average is $68.87. The company has a market cap of $6.06 billion, a price-to-earnings ratio of 22.42 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter last year, the firm earned $1.53 earnings per share. The firm’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts predict that Lantheus will post 4.26 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Lantheus by 1.7% during the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares during the last quarter. M&T Bank Corp acquired a new stake in Lantheus in the fourth quarter valued at $370,950,000. Farallon Capital Management LLC grew its holdings in Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the last quarter. Reinhart Partners LLC. increased its position in shares of Lantheus by 15.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after buying an additional 214,820 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Lantheus by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after buying an additional 44,374 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Key Headlines Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Lantheus reported first-quarter EPS of $1.46, beating estimates of $1.25, on revenue of $377.3 million, also above expectations. The beat suggests solid underlying demand and execution. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company issued FY2026 EPS guidance of $5.00 to $5.25, slightly above the consensus estimate, reinforcing expectations for continued profitability. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Citizens JMP raised its price target to $115 from $85 and reiterated a Market Outperform rating, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Mizuho also lifted its price target to $100 from $95 and kept an Outperform rating, adding to the bullish post-earnings analyst momentum. Benzinga
• Neutral Sentiment: Several follow-up stories highlighted valuation and the earnings call transcript, but these were mainly commentary on the already-reported results rather than new catalysts. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.